Co-Pay Models and AFPs Shift Costs but Raise Access Concerns: Patty Taddei-Allen, PharmD, MBA

Why It Matters

These strategies can lower payer spend but increase financial burden and access gaps for patients, prompting regulators and employers to reassess benefit designs.

Key Takeaways

• Co-pay accumulators shift costs to patients while keeping benefit design unchanged
• Maximizer models expose patients to high out-of-pocket expenses throughout the year
• AFPs remove expensive drugs from formulary, routing patients to manufacturer assistance
• AFPs lower plan liability but can jeopardize patient access and continuity

Pulse Analysis

The surge in prescription‑drug spending has forced insurers and pharmacy benefit managers to adopt more aggressive cost‑containment tools. Co‑pay accumulators and maximizers emerged as extensions of traditional benefit designs, allowing plans to preserve manufacturer rebates while nudging patients toward higher out‑of‑pocket contributions. These mechanisms are attractive to payers because they do not require wholesale formulary changes, yet they subtly reallocate financial risk. As employers seek to manage health‑care budgets, understanding the mechanics of these models is becoming a strategic priority.

Accumulators track a patient’s yearly spending against a threshold, after which the plan stops covering co‑pay assistance, effectively capping the benefit. Maximizers operate similarly but often tie assistance to specific drug tiers, pushing patients into higher cost‑share brackets. Both designs keep the formulary intact, preserving rebate revenue for the plan sponsor, but they expose patients to unpredictable out‑of‑pocket spikes, especially for chronic therapies. The hidden shift of costs can erode medication adherence, prompting clinicians to question whether short‑term savings outweigh long‑term health outcomes.

Alternative funding programs take a more radical approach by removing high‑cost agents from the formulary and directing beneficiaries to manufacturer assistance or charitable foundations. While this reduces the plan’s direct liability, it introduces variability in drug availability and continuity of care, as external programs may have eligibility criteria or limited supply. Employers and regulators are therefore scrutinizing AFPs for potential compliance risks and equity concerns. A balanced pharmacy benefit strategy will need to blend cost control with transparent patient communication to avoid unintended access barriers.